PI-88 in Hepatocellular Carcinoma After Hepatectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

PI-88

Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks

Trial Locations (6)

100

National Taiwan University Hospital, Taipei

333

Chang Gung Memorial Hospital-Linkou Medical Centre, Taoyuan District

404

China Medical University Hospital, Taichung

407

Taichung Veterans General Hospital, Taichung

704

National Cheng Kung University Hospital, Tainan City

813-46

Kaohsiung Veterans General Hospital, Kaohsiung City

All Listed Sponsors
collaborator

Medigen Biotechnology Corporation

INDUSTRY

lead

Cellxpert Biotechnology Corp.

INDUSTRY